Award Recognizes Entrepreneurial Excellence
LAWRENCEVILLE, N.J., June 30 /PRNewswire/ -- Aton Pharma, Inc. announced today that its Chief Executive Officer, Michael G. Wells, has received the Ernst & Young Entrepreneur Of The Year(R) 2009 Award in the emerging companies category in New Jersey. According to Ernst & Young LLP, the award recognizes outstanding entrepreneurs who are building and leading dynamic, growing businesses. Mr. Wells was selected by an independent panel of judges, and the award was presented at a gala event at the Teaneck Marriott at Glenpointe on Tuesday, June 23rd, 2009.
"I'm proud that our hard work at Aton Pharma has been publicly recognized and that we are able to make a contribution to our region's economy," said Wells. "We are continuing our commitment to expanding access to our portfolio of medically essential therapeutics in ophthalmology, acute care and orphan diseases. We take great pride in helping the patients who use our products enjoy improved outcomes and a better quality of life."
The Ernst & Young Entrepreneur Of The Year awards celebrate their 23rd anniversary this year. The program honors entrepreneurs who have demonstrated exceptionality in such areas as innovation, financial performance and personal commitment to their businesses and communities.
Aton Pharma's products include Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert), a preservative-free, once-daily*, sustained release prescription insert indicated for moderate to severe dry eye. Aton recently acquired the U.S. marketing rights to the TIMOPTIC(R) product line from Merck & Co., Inc., including TIMOPTIC in OCUDOSE(R), the only preservative-free medication for glaucoma available in the U.S.
Lacrisert has been FDA-approved for use in patients with moderate to severe dry eye and available by prescription for more than two decades. Unlike artificial tear substitutes that have a residence time measured in minutes, Lacrisert provides continual lubrication and protection to the surface of the eye for all-day relief. Lacrisert acts to stabilize and thicken the pre-corneal tear film and prolong the tear film breakup time, which is usually accelerated in patients with dry eye states. Information and educational video content are available at www.Lacrisert.com.
Most adverse reactions with Lacrisert were mild and transient and included transient blurring of vision, ocular discomfort or irritation, matting or stickiness of eyelashes, photophobia, hypersensitivity, edema of the eyelids and hyperemia. Lacrisert should not be used by patients who are hypersensitive to hydroxypropyl cellulose. If improperly placed, Lacrisert may result in corneal abrasion.
About TIMOPTIC(R) in OCUDOSE(R)
TIMOPTIC(R) (timolol maleate ophthalmic solution) in OCUDOSE(R) (sterile ophthalmic unit dose dispenser) is a preservative-free, non-selective beta-adrenergic receptor blocking agent indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Preservative-free TIMOPTIC is provided in OCUDOSE, a clear low density polyethylene unit dose container, as a sterile, isotonic, buffered, aqueous solution of timolol maleate in two dosage strengths, 0.25 percent and 0.5 percent.
TIMOPTIC in OCUDOSE is contraindicated in patients with bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease; sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure; cardiogenic shock; or hypersensitivity to any component of this product. Because of the potential effects of beta-adrenergic blocking agents on blood pressure and pulse, these agents should be used with caution in patients with cerebrovascular insufficiency. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical ophthalmic administration.
About Aton Pharma
Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global, diversified specialty pharmaceutical company providing essential treatments for under-treated diseases. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of ten products, with sales in over 30 countries, focuses on ophthalmic diseases, orphan conditions and acute care hospital products. For more information, see www.atonrx.com.
* Some patients may require the flexibility of twice-daily dosing for optimal results.
|SOURCE Aton Pharma, Inc.|
Copyright©2009 PR Newswire.
All rights reserved